ReviewImmunologic research1992
Expression, regulation and function of human Fc epsilon RII (CD23) antigen.
Review in Immunologic research, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 39 citations in OpenAlex.
- What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.Cancers · 2024Article
- Decreased levels of sCD21 and sCD23 in blood of patients with systemic-juvenile arthritis, polyarticular-juvenile arthritis, and pauciarticular-juvenile arthritis.Rheumatology international · 2012Article
- CD23/FcεRII: molecular multi-tasking.Clinical and experimental immunology · 2010Review
- Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.Medical oncology (Northwood, London, England) · 2007Article
- CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2002Review
- Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).Clinical and experimental immunology · 2000Article
- Immunodeficiency due to a unique protracted developmental delay in the B-cell lineage.Clinical and diagnostic laboratory immunology · 1999Article
- CD23 (FcepsilonRII) release from cell membranes is mediated by a membrane-bound metalloprotease.The Biochemical journal · 1998Article
- The absence of the transcription activator TFE3 impairs activation of B cells in vivo.Molecular and cellular biology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD23, also known as the low affinity receptor for IgE (Fc epsilon RII), belongs to a novel superfamily of type-II integral membrane proteins. Fc epsilon RII expression was originally described on B cells but subsequent studies showed that CD23 is expressed on a variety of hematopoietic cells and is regulated by several cytokines (i.e., interleukin-4, interferons) in a tissue-specific manner. In some pathological conditions such as B-chronic lymphocytic leukemia, the CD23 gene is abnormally regulated resulting in CD23 overexpression. CD23 is not only an IgE receptor but also a membrane-bound precursor of soluble molecules that still bind IgE (sCD23 or IgE-binding factors). The functions of membrane CD23 are IgE-dependent and vary according to the cell types on which it is expressed. In contrast, sCD23, in addition to being an IgE regulatory molecule, displays multiple cytokine activities that are IgE-independent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.